Hepatology Review

**Update on Liver Transplantation - Frank DiPaola, MD and Daniel Kaul, MD**
Select pediatric candidates for liver transplantation based on appropriateness of the indication and predicted improvement in survival and outcome; Summarize the factors that determine priority for organ allocation in pediatric patients; Develop strategies for optimizing medical management and surgical techniques to improve outcomes in GE 30 - 11

**Chronic Liver Disease - William D. Carey, MD and Norman L. Sussman, MD**
Evaluate the benefits and limitations of liver biopsies, transient elastography, and serum markers for assessment of liver fibrosis and cirrhosis; Apply protocols for noninvasive assessment of liver fibrosis and cirrhosis in patients with viral hepatitis, nonalcoholic fatty liver disease, or autoimmune hepatitis; Summarize dietary and lifestyle factors associated with recent trends in obesity in the United States; Explain how drugs and different types of carbohydrates influence fatty acid synthesis and export in the liver; Prescribe lifestyle interventions to improve metabolic health in patients at high risk for fatty liver disease. GE 30 - 21

**NASH and Acute Liver Failure - Kris V. Kowdley, MD and Norman L. Sussman, MD**
Identify clinical and histologic risk factors for NASH; Discuss the benefits and drawbacks of liver biopsy for identification of NASH in patients with nonalcoholic fatty liver disease (NAFLD); Estimate the accuracy of noninvasive methods for predicting liver fibrosis in patients with NAFLD; Summarize potential targets for pharmaceutical treatment of NASH; Manage patients with hepatic obstruction based on degree of veno-occlusion and severity of liver disease. GE 30 - 22

**Diabetes and Liver Disease - Bart Staels, PhD**
Discuss potential ways of overcoming limitations in diagnosis, assessment of disease progression, and management of NAFLD and NASH; Identify environmental and genetic factors associated with rapid disease progression; Summarize targets for drugs that reduce the progression of NASH or liver fibrosis; Individualize treatment for patients with metabolic syndrome based on which organs show abnormal function. DI 08 - 05

**Liver Transplantation 2017 - Julie K. Heimbach, MD and Christopher J. Sonnenday, MD**
Analyze recent data on the association between obesity and outcomes of hepatic resection and liver transplantation; Apply standardized approaches for weight loss in the treatment of obese candidates for liver transplantation; Explain the allocation of donor organs based on assessment of need and predicted survival rate after transplantation; Recognize the benefits and drawbacks of recent policy changes for improving access to liver transplantation; Assess potential sources of donors in liver transplantation to reduce the gap between supply and demand. GE 31 - 02

**Hepatocellular Carcinoma - Amit Singal, MD and Neehar Parikh, MD**
Analyze current and future epidemiologic trends in risk factors for HCC in the United States; Maximize the effectiveness of surveillance for HCC in clinical practice; Optimize the use of diagnostic evaluation and treatment modalities for patients with HCC; Recognize factors that increase risk for acute cellular rejection or treatment failure following LT. Identify patients with HCC who are likely to benefit from LT with or without prior downstaging. ON 08 - 10

---

**Price:**
Full - $580 / Short - $485

**Register:**
(866) 611-5599 or www.AmericanSeminar.com

*Special Association accreditation may vary. See website.*
Liver Problems - Manish Thapar, MD, David A. Sass, MD and Scott Fink, MD
Manage cerebral edema, coagulopathy, and renal failure associated with acute liver failure; Summarize diagnostic criteria for acute kidney injury in patients with chronic liver disease; Treat hepatorenal syndrome using pharmacologic or surgical therapies; Identify risk factors for rapid progression of hepatic varices to variceal hemorrhage; Use pharmacologic and endoscopic interventions to manage hepatic varices and variceal hemorrhage.
GE 31 - 13

Hepatitis B/Hepatitis C - Camilla S. Graham, MD and Lawrence R. Crane, MD
Elaborate on the replication and life cycle of HBV and how these are used as potential targets for therapy; Perform screening tests to identify individuals who can benefit from HBV immunization, individuals exposed to HBV, and individuals with chronic HBV infection; Identify barriers to curing HBV infection; Use appropriate scoring systems and tests to stage chronic HCV infection; Minimize drug-drug interactions between direct-acting antivirals.
IM 64 - 27

Complications of Liver Disease - Adrian Reuben, MD and Joseph DiNorcia
List causes of poor surgical outcomes in patients with liver disease; Evaluate risk for perioperative morbidity and mortality according to severity of cirrhosis and type of surgical procedure; Provide appropriate screening and diagnostic tests for patients at high risk for HCC; Treat HCC based on size and number of lesions, liver function, and eligibility for surgery; Consider procedures for inducing liver hypertrophy or downstaging HCC prior to resection or transplantation.
GE 31 - 14

Complications of Liver Transplantation - Ali Zarrinpar, MD, Elaine Cheng, MD and Christina Lindenmeyer, MD
Select patients with HCC who are most likely to benefit from liver transplantation; Identify methods to increase the donor pool for liver transplantation; Compare ex vivo methods for preserving the function of donor livers; Use a scoring system to predict outcomes of patients in the ICU; Choose among liver-specific scoring systems to determine risk for death among patients with cirrhosis staying in the ICU.
GE 31 - 15